Loading clinical trials...
Loading clinical trials...
Effect of Total Intravenous Anesthesia With Remimazolam vs Sevoflurane Inhalation Anesthesia on Incidence of Emergence Agitation and Complications in Children Undergoing Ophthalmic Surgery
As a novel ultra-short-acting benzodiazepines drugs, Remimazolam has been accepted for induction and maintenance of clinical anesthesia. Compared to the traditional benzodiazepines drugs, Remimazolam combines the safety of midazolam with the effectiveness of propofol, and also has the advantages of acting quickly, short half-life, no injection pain, slight respiratory depression, independent of liver and kidney metabolism, long-term infusion without accumulation, and has a specific antagonist: flumazenil. This study aims to investigate whether Remimazolam reduces the incidence of emergence agitation in children after ophthalmic surgery, compared to sevoflurane (RCT).
Age
3 - 8 years
Sex
ALL
Healthy Volunteers
No
the Second Affiliated Hospital of Nanchang University, Nanchang University
Nanchang, Jiangxi, China
Start Date
August 23, 2022
Primary Completion Date
February 6, 2023
Completion Date
February 7, 2023
Last Updated
March 24, 2023
110
ACTUAL participants
Remimazolam
DRUG
Sevoflurane
DRUG
Fentanyl
DRUG
Cisatracurium Besylate
DRUG
Remifentanil
DRUG
Lead Sponsor
Second Affiliated Hospital of Nanchang University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions